Yang Sheng-yue, Shen Jun-li, Feng En-zhi, Xu Jun, Huang Ning-xia, Zhao Li-hong, Wu Xue-mei, Zhang Dong-tian, Zhang Ying
Department of Respiratory Disease of Lanzhou Command, the Fourth Hospital of PLA, Xi'ning 810007, Qinghai, China.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2006 Dec;18(12):727-9.
To assess the role of serum basic fibroblast growth factor (bFGF) in the development of hypoxic pulmonary hypertension in the patients with chronic cor pulmonale on highland (HACCP).
The levels of bFGF in serum of 38 patients with HACCP in the acute exacerbation stage, 30 patients with chronic obstructive pulmonary disease (COPD) in the remission stage and 30 normal control subjects were measured by sandwich enzyme-linked immunoadsorbent assay (ELISA). The mean pulmonary arterial pressure (MPAP) was measured by echocardiography. The partial pressure of oxygen in artery blood (PaO(2)) was measured by blood gas analyzer.
The level of serum bFGF [(87.54+/-12.15) ng/L] and MPAP [(45.86+/-5.63)mm Hg (1 mm Hg=0.133 kPa)] in the patients with HACCP were significantly higher than those in the patients with COPD [(55.72+/-9.08) ng/L, (22.95+/-2.56)mm Hg, respectively, both P<0.01], those of the patients with COPD were both significantly higher than those of the normal control subjects [(49.83+/-8.78)ng/L, (20.34+/-2.23)mm Hg, respectively, both P<0.05]. The PaO(2) [(38.79+/-4.56)mm Hg] in the patients with HACCP was significantly lower than those in patients with COPD and normal subjects [(58.22+/-6.18) mmHg and (66.57+/-5.48)mm Hg, respectively, all P<0.01]. The level of serum bFGF in the patients with HACCP and the patients with COPD was positively correlated with MPAP (cor pulmonale group r=0.788, P<0.01; COPD group r=0.674, P<0.01)],negatively correlated with PaO(2) (cor pulmonale group r=-0.735, P<0.01; COPD group r=-0.587, P<0.01)).
The level of serum bFGF in patients with HACCP is significantly increased; it may play an important role in the process of sustained hypoxic pulmonary hypertension in patients with HACCP.
评估血清碱性成纤维细胞生长因子（bFGF）在高原慢性肺心病（HACCP）患者低氧性肺动脉高压发生发展中的作用。
采用双抗体夹心酶联免疫吸附测定法（ELISA）检测38例HACCP急性加重期患者、30例慢性阻塞性肺疾病（COPD）缓解期患者及30例正常对照者血清中bFGF水平。采用超声心动图测量平均肺动脉压（MPAP）。采用血气分析仪测量动脉血氧分压（PaO₂）。
HACCP患者血清bFGF水平[（87.54±12.15）ng/L]和MPAP[（45.86±5.63）mmHg（1 mmHg = 0.133 kPa）]显著高于COPD患者[分别为（55.72±9.08）ng/L、（22.95±2.56）mmHg，P均<0.01]，COPD患者的这两项指标均显著高于正常对照者[分别为（49.83±8.78）ng/L、（20.34±2.23）mmHg，P均<0.05]。HACCP患者的PaO₂[（38.79±4.56）mmHg]显著低于COPD患者和正常对照者[分别为（58.22±6.18）mmHg和（66.57±5.48）mmHg，P均<0.01]。HACCP患者和COPD患者血清bFGF水平与MPAP呈正相关（肺心病组r = 0.788，P<0.01；COPD组r = 0.674，P<0.01），与PaO₂呈负相关（肺心病组r = -0.735，P<0.01；COPD组r = -0.587，P<0.01）。
HACCP患者血清bFGF水平显著升高；其可能在HACCP患者持续性低氧性肺动脉高压的发生过程中起重要作用。
